Janssen Pharmaceutica Nv

Glaxosmithkline Intellectual Property Development Limited

Theracos Sub, LLC

Glaxo Group Limited

Sap Se

Janssen Sciences Ireland Unlimited Company

Theracos, Inc.

Jiaohong Biotechnology (shanghai) Co., Ltd.

Qian Liu

Zhao-Kui Wan

Wing Shun Cheung

Brian Seed

Jacques Y Roberge

Binhua Lv

Haibing Guo

Ge Xu

Luoheng Qin

Mengzhuang Cai

Zehong Wan

Xiao Ding

Baowei Zhao

Yingxia Sang

Luigi Piero Stasi

Feng Ren

Yimin Jiang

Xuedong Dai

Colin Michael Edge

Gang Deng

Jose Luis Castro Pineiro

Bernhard Thimmel

Yanping Xu

Xichen Lin

Yan Feng

Daniele Andreotti

Martin Scholz

David Robert Vesey

Weiqiang Xing

Zhanling Cheng

Hailong Wang

Kai Long

Yun Jin

Chao Liang

Yang Zhan

Andrew John Eatherton

Liqiang Fu

Heike Klews

Karamjit Singh Jandu

Oliver James Philps

Johannes Fenzl

Tobias Poeppke

Qiongfeng Xu

Kevin Meng

Yuesheng Chong

Guanhua Xun

The invention relates to new thienopyridinone compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and to their use in the treatment of diseases, e.g. cancer.

Thienopyridinone compounds

Provided are a method for detecting a nucleic acid based on prokaryotic Argonaute protein and an application thereof. In particular, provided is a system for detecting a target nucleic acid molecule. The system comprises guide ssDNA, a gene-editing enzymeArgonaute (PfAgo), and a fluorescent reporter nucleic acid.

Method for detecting nucleic acid based on prokaryotic argonaute protein and application thereof

Pyrazolopyridinone compounds, the pharmaceutical compositions comprising said compounds, and the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and their use in the treatment of diseases, e.g. cancer.

Pyrazolopyridinone compounds

A method may include generating a first user interface for providing, to a client, a first selection of inputs for attributes of a rule scenario for defining a rule. The rule may be applied to modify a data processing functionality of the application. Parameters of the rule may be determined based on the rule scenario and a first input from the first selection of inputs being selected via the first user interface. The parameters of the rule may correspond to data objects affected by the application of the rule. A second user interface for providing, to the client, a second selection of inputs for defining a condition of the rule may be generated. The condition of the rule may evaluate the parameters of the rule. The rule may be generated based on a second input from the second selection of inputs being selected via the second user interface.

Rule scenario framework for defining rules for operating on data objects

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject, and the compound has the structure of Formula I including any possible deuterated isomers, stereoisomers or tautomeric forms thereof.

Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections

The invention relates to new quinolinone compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and to their use in the treatment of diseases, e.g. cancer.

Quinolinone compounds

The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases

Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.

Crystalline form of benzylbenzene SGLT2 inhibitor

Disclosed are substituted fused pyrazoles, for example substituted indazoles, that inhibit LRRK2 kinase activity, pharmaceutical compositions containing them and their use in the treatment of Parkinson's disease.

Substituted fused pyrazole compounds and their use as LRRK2 inhibitors

The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

LRRK2 inhibitors for the treatment of Parkinson's disease

Compounds

The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease or Alzheimer's disease.

2-(benzyloxy) benzamides as LRRK2 kinase inhibitors

Growing community of inventors

Shanghai, China

Qian Liu